Monimus Capital Management LP purchased a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 42,067 shares of the biopharmaceutical company's stock, valued at approximately $664,000. Monimus Capital Management LP owned approximately 0.66% of Assembly Biosciences at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Peapod Lane Capital LLC bought a new stake in Assembly Biosciences in the 4th quarter valued at about $994,000. JPMorgan Chase & Co. raised its position in shares of Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 3,442 shares during the period. FMR LLC lifted its holdings in shares of Assembly Biosciences by 29.7% in the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company's stock worth $240,000 after purchasing an additional 3,635 shares in the last quarter. Finally, Palumbo Wealth Management LLC acquired a new stake in Assembly Biosciences in the 4th quarter valued at $180,000. Institutional investors and hedge funds own 19.92% of the company's stock.
Insider Activity
In other news, Director Michael Houghton bought 3,202 shares of the firm's stock in a transaction on Monday, December 30th. The stock was acquired at an average cost of $15.61 per share, with a total value of $49,983.22. Following the completion of the transaction, the director now directly owns 3,202 shares of the company's stock, valued at $49,983.22. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 5.10% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "neutral" rating on shares of Assembly Biosciences in a research note on Friday, December 27th.
Check Out Our Latest Stock Analysis on Assembly Biosciences
Assembly Biosciences Price Performance
ASMB traded down $0.41 during mid-day trading on Wednesday, reaching $10.85. 13,173 shares of the stock were exchanged, compared to its average volume of 24,367. The company has a 50 day moving average price of $13.25 and a two-hundred day moving average price of $15.24. Assembly Biosciences, Inc. has a 1 year low of $10.27 and a 1 year high of $19.93.
About Assembly Biosciences
(
Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Read More
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
